<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="178552">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00770679</url>
  </required_header>
  <id_info>
    <org_study_id>NA00002253</org_study_id>
    <nct_id>NCT00770679</nct_id>
  </id_info>
  <brief_title>Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging</brief_title>
  <official_title>Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cholesterol-lowering drugs called statins improve the functioning of the endothelium, and
      help prevent heart disease. We are testing whether statins improve endothelial function more
      in the arteries that have worse endothelium to begin with. One of the functions of the
      endothelium is to help control how blood vessels dilate (expand) or contract (narrow) in
      different situations. This affects how blood flows through those vessels. Magnetic resonance
      imaging (MRI) can be used to evaluate endothelial function in the arms and legs
      noninvasively. You are being asked to participate in a study using MRI to test whether a
      3-week course of statins improves the endothelium of legs more than it improves the
      endothelium of arms.

      Adults with type 2 diabetes may join.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Correct
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">June 2010</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Femoral hyperemic shear rate</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lipitor</intervention_name>
    <description>80 mg everyday (QD) for 3 weeks</description>
    <other_name>atorvastatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 40-90

          -  Male or female

          -  Type 2 diabetes

        Exclusion Criteria:

          -  Known pregnancy or nursing.

          -  Females of child bearing potential must have been surgically sterilized or be post
             menopausal.

          -  Smoking

          -  Known vascular disease

          -  Inability to complete MRI scan

          -  Symptoms of claudication

          -  Use of a nitrate medicine

          -  Use of any cholesterol-lowering agent

          -  LDL &lt; 70

          -  Acute illness

          -  Liver disease

          -  Contraindication to getting an MRI scan (i.e. electronic implant, shrapnel, cerebral
             aneurysm clip, welding history).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harry Silber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>JHU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harry SIlber, MD</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Herr, RN</last_name>
      <phone>410-550-5127</phone>
      <email>mherr@jhmi.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <lastchanged_date>August 3, 2009</lastchanged_date>
  <firstreceived_date>October 9, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Harry Silber, MD</name_title>
    <organization>JHU</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
